12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tivopath tivozanib regulatory update

Aveo and partner Astellas said FDA accepted for review an NDA for Tivopath tivozanib to treat renal cell carcinoma (RCC). FDA did not grant Aveo's request for 6-month Priority...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >